Published Year: 2024
Wound Debridement Market - A Global and Regional Analysis: Focus on Product, Region, Country-Level A
The global wound debridement market was valued at $1,272.0 million in 2023 and is expected to...
Market Research Report
A quick peek into the report
Global Wound Biologics Market Industry Overview
The global wound biologics market was valued at $1,851.4 million in 2022 and is anticipated to grow to $3,321.5 million by the end of 2030. This market is expected to expand at a compound annual growth rate (CAGR) of 7.71% between 2023 and 2030. Such growth is being experienced by the wound biologics market, owing to increasing demand for treating wounds and burn injuries. Drivers of this growth include the rising incidence of burn injuries, the expanding prevalence of diabetic foot ulcers and pressure ulcers, and government-led initiatives aimed at enhancing wound care treatments.
Market Introduction
Wound biologics products are advanced medical materials derived from biological sources such as human cells, tissues, or natural substances. These products are specifically designed to facilitate wound healing and tissue regeneration in patients with various types of wounds, including chronic wounds such as diabetic ulcers, pressure ulcers, and venous ulcers, as well as acute wounds from injuries or surgeries. Wound biologics can include growth factors, extracellular matrices, cellular therapies, and bioengineered skin substitutes, all aimed at promoting the natural healing processes of the body to achieve better wound closure and tissue repair. One recent development that has taken place in the market was in March 2023 when BioTissue completed a facility expansion and renovation in Doral, Florida, to support the growing demand and future expansion of its biologics product portfolio.
Market Segmentation:
Segmentation 1: by Product
• Growth Factors
• Skin Substitutes
• Topical Agents
Skin Substitutes to Lead the Global Wound Biologics Market (by Product)
Based on product, the wound biologics market is led by skin substitutes, which held a 63.78% share in 2022.
Segmentation 2: by Region
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Netherlands
o Switzerland
o Russian Federation
o Turkey
o Poland
o Belgium
o Sweden
o Ireland
o Norway
o Austria
o Denmark
o Finland
o Portugal
o Czech Republic
o Romania
o Greece
o Slovakia
o Ukraine
• Asia-Pacific
o Japan
o China
o India
o South Korea
o Australia
o Malaysia
o Thailand
• Latin America
o Brazil
o Mexico
o Colombia
o Argentina
o Chile
• Rest-of-the-World
Regionally, North America maintains a dominant position, and it is expected to grow through a steady compound annual growth rate (CAGR) of 6.66% from 2023 to 2030. This sustained growth can be attributed to the region's advanced healthcare infrastructure, widespread awareness of wound management, and a notable increase in chronic wounds among its aging populace.
The emphasis on R&D in North America has also facilitated the emergence of innovative wound biologics products, supported by a strong regulatory environment and healthcare policies favouring advanced wound care solutions. The emphasis on R&D in North America has also facilitated the emergence of innovative wound biologics, supported by a strong regulatory environment and healthcare policies favouring advanced wound care solutions.
Asia-Pacific and the Rest-of-the-World regions are projected to experience the highest growth rates, with CAGRs of 11.49% and 11.29%, respectively, indicating a rapidly expanding market presence. The growth in these regions is likely driven by improving healthcare infrastructure, rising awareness of effective wound care, and increasing accessibility to advanced medical treatments. Overall, the wound biologics market globally has been characterized by regional growth patterns influenced by healthcare advancements, demographic shifts, and a collective focus on improving wound care outcomes.
Recent Developments in the Wound Biologics Market
• In May 2023, Cellularity disclosed a significant purchase order amounting to $45 million in accordance with the first private label agreement in the Middle East for Cellularity Inc.'s halal-certified biomaterial products. The products, namely Biovance, Biovance 3L, Interfyl, and CentaFlex have obtained halal certification.
• In January 2022, Gunze Limited announced the commencement of Epiflex sales by Gunze Medical Limited, marking the first and only approved product available in Japan. It is important to note that Epiflex is a registered trademark of MiMedx Group, Inc.
Analyst’s Thoughts
According to Swati Sood, Principal Analyst – BIS Research, "the wound biologics market is poised for significant growth, driven by the rising global incidence of chronic wounds and advancements in wound care technology. With a projected CAGR of 7.71% through 2030, market players are focusing on geographical expansion by entering new markets and strengthening their presence in existing ones. This may involve strategic acquisitions, partnerships with local distributors, or establishing direct sales channels. Also, educating healthcare professionals and patients about the benefits of advanced wound biologics and promoting patient engagement in self-care is another strategic focus.
Collaboration with research institutions, biotechnology firms, and academic centers allows market players to access cutting-edge technologies, novel biomaterials, and expertise in biologic development, enhancing their competitive edge."
Wound Biologics Market - A Global and Regional Analysis
Focus on Product, Region, Country-Level Analysis, and Competitive Landscape Analysis and Forecast, 2023-2030
Some Faq's
Frequently Asked Questions
Ans: Wound Biologics products are advanced medical materials derived from biological sources such as human cells, tissues, or natural substances. These products are specifically designed to facilitate wound healing and tissue regeneration in patients with various types of wounds, including chronic wounds such as diabetic ulcers, pressure ulcers, and venous ulcers, as well as acute wounds from injuries or surgeries. Wound biologics can include growth factors, extracellular matrices, cellular therapies, and bioengineered skin substitutes, all aimed at promoting the natural healing processes of the body to achieve better wound closure and tissue repair.
Ans: Existing market players in the wound biologics market are adopting various strategic initiatives to consolidate their market position and respond to the dynamic needs of wound care. Companies are heavily investing in R&D to introduce new and improved wound biologics that feature advanced materials, offer better wound healing properties, and enhance patient comfort. Companies are investing in research and development to introduce innovative wound biologics with advanced features.
Market players are expanding their presence into new geographic regions and emerging markets to tap into growing opportunities and establish a strong foothold in key regions. Implementing value-based pricing models and collaborating with payers to secure favourable reimbursement policies for biologic wound therapies improves affordability and access for patients.
Ans: The following are the USPs of this report:
• Wound biologics market opportunities across regions
• Competitive landscape of the wound biologics industry
• Wound biologics industry overview in the next decade
• Detailed regional analysis of the market
• Key strategies and developments in the market
• Ecosystems of the key companies
Ans: A regional analysis of the wound biologics report would be valuable to a range of stakeholders interested in understanding the market dynamics and opportunities within specific geographic regions. Companies involved in the production and distribution of wound biologics can use regional analysis to identify market opportunities, assess regional competition, and tailor their marketing and distribution strategies to specific geographic areas.
Similar Product
You may also like